Hana Pharm Co., Ltd.

A293480

KR7293480000

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
12,780 ^KRW	-1.77%		-3.55%	-8.39%

2023	Singapore Shares Return to Green; Hyphens Pharma Rises 5% on Deal to Develop Sedation Drug in Singapore	MT
2023	Hyphens Pharma to Develop, Commercialize Hana Pharm's Sedation Drug in Singapore	MT

Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.

February 04, 2020 at 09:11 pm EST

From October 1, 2019 to December 31, 2019, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 87,239 shares, representing 0.54% for KRW 1,997.13 million under the buyback announced on August 6, 2019.

Latest news about Hana Pharm Co., Ltd.

Singapore Shares Return to Green; Hyphens Pharma Rises 5% on Deal to Develop Sedation Drug in Singapore	23-05-18	MT
Hyphens Pharma to Develop, Commercialize Hana Pharm's Sedation Drug in Singapore	23-05-18	MT
Hyphens Pharma Pte. Ltd. Signs an Exclusive Sub-License and Supply Agreement with Hana Pharm Co., Ltd. to Develop and Commercialise Byfavo® 20mg in Singapore	23-05-17	CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine	22-04-12	MT
Hana Pharm Receives Market Approval for Byfavo (Remimazolam) in Procedural Sedation in South Korea	21-08-31	CI
Hana Pharm Informs PAION AG About the Launch of Byfavo™ (Remimazolam) for the Use in General Anesthesia in South Korea	21-04-07	CI
Hana Pharm Co., Ltd's Equity Buyback announced on August 19, 2019, has expired.	20-02-17	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.	20-02-04	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.	20-02-04	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.	20-02-04	CI
Hana Pharm Co., Ltd's Equity Buyback announced on August 6, 2019, has expired with 87,239 shares, representing 0.54% for KRW 1,997.13 million.	20-02-04	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on July 9, 2019.	20-01-07	CI
Hana Pharm Co., Ltd's Equity Buyback announced on July 9, 2019, has expired.	20-01-07	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on July 26, 2019.	19-10-30	CI
Hana Pharm Co., Ltd's Equity Buyback announced on July 26, 2019, has expired with 84,312 shares, representing 0.53% for KRW 1,997.08 million.	19-10-29	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 1,000 million worth of its shares.	19-08-19	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	19-08-18	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.	19-08-05	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	19-08-05	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.	19-07-26	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	19-07-25	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.	19-07-09	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	19-07-08	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on December 21, 2018.	19-06-20	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on December 21, 2018.	19-06-20	CI

Chart Hana Pharm Co., Ltd.

Duration

Period

More charts

Company Profile

HANA PHARM CO., LTD is a Korea-based company mainly engaged in the manufacturing and distribution of specialty pharmaceuticals. The companyâs main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The Company also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
HANA PHARM CO., LTD.	-8.39%	166M
MERCK KGAA	+17.18%	79.38B
KYOWA KIRIN CO. LTD.	+9.28%	8.74B
SK BIOPHARMACEUTICALS CO., LTD.	-14.24%	4.94B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+49.95%	4.7B
YUHAN CORPORATION	+5.96%	3.98B
INDIVIOR PLC	+11.14%	2.28B
BETTA PHARMACEUTICALS CO., LTD.	-23.57%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+17.77%	2.14B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-32.28%	2.12B

Specialty & Advanced Pharmaceuticals

Hana Pharm Co., Ltd.

Equities

A293480

KR7293480000

Pharmaceuticals

Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.

Latest news about Hana Pharm Co., Ltd.

Chart Hana Pharm Co., Ltd.

Company Profile

Sector Specialty & Advanced Pharmaceuticals